OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript
OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript
Seeking Alpha10/30/2026Neutral
OABI
OmniAb Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$733.68M
P/E Ratio
—
EPS
$-0.34
Beta
1.36
52W High
$5.43
52W Low
$1.35
50-Day MA
$4.69
200-Day MA
$2.77
Dividend Yield
—
Profit Margin
-108.10%
Forward P/E
—
PEG Ratio
—
About OmniAb Inc.
OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. This proprietary technology enables the rapid identification and optimization of effective therapies across various disease areas, thereby enhancing the likelihood of successful clinical outcomes. By establishing strategic partnerships and collaborations, OmniAb streamlines its drug development processes and improves access to groundbreaking treatments. Supported by a seasoned leadership team and a robust pipeline of product candidates, the company is strategically positioned to capitalize on the growing opportunities within the biopharmaceutical industry.
Fundamentals
| Revenue (TTM) | $40.21M |
| Gross Profit (TTM) | $39.27M |
| EBITDA | $-20.31M |
| Operating Margin | -409.90% |
| Return on Equity | -16.50% |
| Return on Assets | -7.78% |
| Revenue/Share (TTM) | $0.31 |
| Book Value | $1.71 |
| Price-to-Book | 2.82 |
| Price-to-Sales (TTM) | 18.25 |
| EV/Revenue | 16.34 |
| EV/EBITDA | -10.62 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 78.30% |
| Shares Outstanding | $145.86M |
| Float | $118.70M |
| % Insiders | 15.24% |
| % Institutions | 52.35% |
Historical Volatility
HV 10-Day
67.25%
HV 20-Day
58.06%
HV 30-Day
64.22%
HV 60-Day
74.23%
HV Rank
45.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($8.33 target)
7
BuyLatest News
OmniAb Q3 Earnings Call Highlights
OmniAb NASDAQ: OABI reported higher third-quarter revenue and raised its full-year 2026 revenue and year-end cash outlook, citing partner-program milestones, expanding service revenue and early commercial progress for its xPloration B-cell screening platform.
MarketBeat10/30/2026Positive
OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.14 per share a year ago.
Zacks Investment Research10/30/2026Neutral
OmniAb to Report Third Quarter 2026 Financial Results on October 30
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on Friday, October 30, 2026, and will hold a conference call that same day beginning at 8:00 a.m. Eastern time. Conference Call and Webcast What: OmniAb conf.
Business Wire10/14/2026Neutral
OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth
OmniAb NASDAQ: OABI used its investor and analyst day to outline its strategy for expanding royalty-bearing partnerships, commercializing its xPloration screening platform and entering the peptide-discovery market through its newly introduced OmniTides platform.
MarketBeat10/7/2026Positive
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy
OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research10/6/2026Positive
OmniAb to Host Investor & Analyst Day on October 6, 2026
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reiterates details of its upcoming Investor & Analyst Day, to be held on October 6, 2026, in Emeryville, CA. The event will feature presentations from OmniAb's executive leadership team, including corporate updates, select partner programs, the xPloration® platform, technology innovations and a Q&A sessi.
Business Wire9/14/2026Neutral
OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech
OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships like the recent Eli Lilly deal. OABI's 110 partners and 425 programs are generating higher, more predictable milestone revenues, with $340M in clinical-stage milestone potential and a $3B+ total milestone pool. The Lilly collaboration validates OABI's technology, offers high-margin, capital-light economics, and has directly improved 2026 cash guidance to $49–$53M.
Seeking Alpha8/18/2026Positive
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb's technology platform and expertise in ion channel discovery and screening. “We are pleased to enter into this important new relationship with Lilly,” said M.
Business Wire8/17/2026Neutral
OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript
OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript
Seeking Alpha8/7/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OABI and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026